This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Tezampanel

Raptor Pharmaceutical Corp.

Drug Names(s): NGX424, LY293558

Description: Tezampanel is a AMPA/kainate (AK) receptor antagonist. AK receptor antagonists selectively block transmission of pain signals mediated through the activation of glutamate receptors.

Deal Structure: TorreyPines and Eli Lilly
In April 2003, TorreyPines Therapeutics (TPTX) entered into an agreement with Eli Lilly to obtain an exclusive license to Eli Lillys AMPA/kainate, or AK, antagonist assets including tezampanel and NGX426. TPTX paid Eli Lilly an up-front license fee of $6 million under the agreement. If specified development, regulatory and commercial milestones are achieved, TPTX will be obligated to make milestone payments to Eli Lilly. TPTX is also obligated to pay royalties to Eli Lilly on any sales of tezampanel and NGX426.

In November 2008, TorreyPines Therapeutics announced that it has purchased from Eli Lilly a reduction in certain royalty amounts that may become payable to Eli Lilly on net sales of TorreyPines clinical-stage compounds NGX426 and tezampanel, should either or both gain regulatory approval. Specifically, the top tier royalty rate will be reduced three percentage points and the middle tier royalty rate will be reduced one half percentage...See full deal structure in Biomedtracker

Partners: Eli Lilly & Company


Tezampanel News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug